BRAF and neoplasm: By contrast, 19 patients receiving 2L treatments did not show tumor progression during the overall observation period and 9 patients still received 2L treatments at the time of data-lock including 5 patients initially treated with BRAF ± MEKi therapy and 4 patients with initial CPI therapy (p = 0.257).